NEXCIDA THERAPEUTICS
Nexcida Therapeutics develops a novel antibiotics to treat serious, life-threatening bacterial infections. The company is led by an outstanding team of proven anti-infectives drug developers and is committed to addressing the emerging threat of drug-resistant bacteria. Nexcida Therapeutics was founded in 2014 and is based in Menlo Park, California.
NEXCIDA THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Life Science
Founded:
2014-01-01
Address:
Menlo Park, California, United States
Country:
United States
Status:
Active
Contact:
6503255156
Total Funding:
2.75 M USD
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
Rebiotic Rx
Rebiotic Rx is develops novel liposomal antibiotics for antibiotic-resistant bacterial infections.
Trius Therapeutics
Trius Therapeutics is focused on the development of innovative antibiotics for life-threatening infections.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
More informations about "Nexcida Therapeutics"
Nexcida Therapeutics - Crunchbase Company Profile & Funding
Nexcida Therapeutics develops a novel antibiotics to treat serious, life-threatening bacterial infections. The company is led by an outstanding team of proven anti-infectives drug โฆSee details»
Nexcida Therapeutics Company Profile 2024: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Nexcida Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Nexcida Therapeutics - Funding, Financials, Valuation & Investors
Nexcida Therapeutics develops a novel antibiotics to treat serious, life-threatening bacterial infections.See details»
Nexcida Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Nexcida Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Nexcida Therapeutics - Products, Competitors, Financials, โฆ
Nexcida Therapeutics is a stealth biotechnology company. You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a โฆSee details»
Canaan, Vivo Capital, Frazier raising $21.3M for stealth startup
Jun 23, 2015ย ยท Three West Coast healthcare venture capital firms โ Canaan Partners, Vivo Capital and Frazier Healthcare โ are teaming up to launch a stealth new startup called โฆSee details»
Nexcida Therapeutics - Tech Company Profile - Gaebler.com โฆ
Jun 30, 2015ย ยท Nexcida Therapeutics, based in Menlo Park, received equity investments from Frazier Technology Ventures, Vivo Capital and Canaan Partners. Company Overview. Contact โฆSee details»
NEXCIDA THERAPEUTICS, INC. :: California (US) - OpenCorporates
Free and open company data on California (US) company NEXCIDA THERAPEUTICS, INC. (company number 3790394), 70 WILLOW RD STE 200 MENLO PARK CA 94025-3652See details»
Nexcida Therapeutics - Crunchbase
Nexcida Therapeutics develops a novel antibiotics to treat serious, life-threatening bacterial infections.See details»
Nexcida Therapeutics Stock Price, Funding, Valuation, Revenue ...
See Nexcida Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on Nexcida Therapeutics's post-money valuation and revenue.See details»
Nexcida Therapeutics โ Vivo Capital | Healthcare Focused โฆ
Jun 19, 2014ย ยท We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.See details»
NEXCIDA THERAPEUTICS, INC. - HIPAASpace
NEXCIDA THERAPEUTICS, INC. BUSINESS ADDRESS EIN 471705155 An Employer Identification Number (EIN) is also known as a Federal Tax Identification Number, and is used โฆSee details»
Nexcida Therapeutics, Inc. in Menlo Park CA - Company Profile
View company leaders and background information for Nexcida Therapeutics, Inc. Search our database of over 100 million company and executive profiles.See details»
Antimicrobial Susceptibility of Pseudomonas aeruginosa to โฆ
Ceftazidime-avibactam and ceftolozane-tazobactam are the most recently U.S. FDA-approved cephalosporinโฮฒ-lactamase inhibitor combinations for treating infections caused by Gram โฆSee details»
NIH, FDA and 15 private organizations join forces to increase โฆ
The National Institutes of Health, U.S. Food and Drug Administration, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of โฆSee details»
Venture Round - Nexcida Therapeutics - 2015-06-08 - Crunchbase
Nexcida Therapeutics raised $2750002 on 2015-06-08 in Venture Round. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ... Venture Round - โฆSee details»
WHO recommends highly successful COVID-19 therapy and calls โฆ
Apr 22, 2022ย ยท Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital โฆSee details»
Nutcracker Therapeutics Presents Precision Biomanufacturing and โฆ
3 days agoย ยท EMERYVILLE, Calif., November 25, 2024--Nutcracker Therapeutics will introduce its CRDMO capabilities to provide scalable biomanufacturing services for RNA drug developers.See details»
Trius Therapeutics - Crunchbase Company Profile & Funding
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. We have successfully โฆSee details»
Home - NextRNA
We identify tissue-specific and disease-driving lncRNAs across therapeutic areas. We validate the role of lncRNAs and characterize lncRNA-RBP interactions driving the mechanism of action in โฆSee details»